GlioCART
Allschwil
About GlioCART
GlioCART is a University of Basel spin-out developing the first CAR-T cell therapy for glioblastoma (GBM), an aggressive brain cancer with median survival of 12-18 months. Its dual-action approach targets tumors directly while secreting a CD47-blocker to reprogram immunosuppressive macrophages in the tumor microenvironment, aiming for better efficacy and reduced side effects than standard care.
Company Facts
- Operating status: Active
- IPO status: Private
- Total funding: $250.5K
- Funding stage: Seed
- Last round: Seed (Nov 2025)
Industries & Categories
Health Care, Therapeutics
Canonical: https://fsome.com/organization/gliocart-185936 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.